Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;54(5):1076-1084.
doi: 10.1007/s43441-020-00116-4. Epub 2020 Feb 6.

How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Thomas Severin  1 , Solange Corriol-Rohou  2 , Christina Bucci-Rechtweg  3 , Kristina An Haack  4 , Sabine Fuerst-Recktenwald  5 , Pirkko Lepola  6 , Ensio Norjavaara  7 , Martine Dehlinger-Kremer  8 ; EFGCP Children’s Medicines Working Party; Sebastian Haertter  9 , S Y Amy Cheung  10 ; IQ Pediatric Working Group
Affiliations

How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

Thomas Severin et al. Ther Innov Regul Sci. 2020 Sep.

Erratum in

Abstract

Background: Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investing in building appropriate structures and capabilities as part of their business strategy to better tackle the challenges and opportunities of pediatric drug development.

Methods: The EFGCP Children's Medicines Working Party and the IQ Pediatric working group have joined their efforts to survey their member company representatives to understand how pharmaceutical companies are organized to fulfill their regulatory obligations and optimize their pediatric drug development programs.

Results: Key success factors and recommendations for a fit-for-purpose Pediatric Expert Group (PEG) were identified.

Conclusion: Pediatric structures and expert groups were shown to be important to support optimization of the development of pediatric medicines.

Keywords: Child; Drug development; Expert group; Medicines for children; Pediatric medicines; Pediatric structures.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest forms have been uploaded for each author. Thomas Severin is employee of Novartis Pharma AG, Basel, Switzerland. Solange Corriol-Rohou is employee of AstraZeneca, Paris, France. Christina Bucci-Rechtweg is employee and stockholder of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Kristina an Haack is employee of Sanofi/Genzyme, Chilly-Mazarin, France. Sabine Fuerst-Recktenwald is employee of F. Hoffmann-La Roche Ltd., Basel, Switzerland. Pirkko Lepola is employee of Helsinki University Hospital, Department of Children and Adolescents, Helsinki, Finland and has no disclosures. Ensio Norjavaara is employee of AstraZeneca, Mölndal, Sweden. Martine Dehlinger-Kremer is employee of Synteract, & EUCROF, Munich, Germany. Sebastian Haertter is employee of Boehringer-Ingelheim, Ingelheim, Germany. S.Y. Amy Cheung is employee of Certara Strategic Consulting, Princeton, New Jersey, USA.

References

    1. Bucci-Rechtweg C. Enhancing the pediatric drug development framework to deliver better pediatric therapies tomorrow. Clin Ther. 2017;39(10):1920–1932. doi: 10.1016/j.clinthera.2017.07.043. - DOI - PubMed
    1. ICH E11(R1) Guideline: Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population. 2017. https://database.ich.org/sites/default/files/E11_R1_Addendum.pdf.
    1. Rivera DR, Hartzema AG. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development. Ann Pharmacother. 2014;48(3):369–379. doi: 10.1177/1060028013514031. - DOI - PubMed
    1. Ren Z, Zajicek A. Review of the best pharmaceuticals for children act and the pediatric research equity act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39(7):530–531. doi: 10.1053/j.semperi.2015.08.006. - DOI - PMC - PubMed
    1. EMA Reflection Paper on the Use of Extrapolation in the Development of Medicines for Paediatrics. EMA/189724/2018. 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-refl....

LinkOut - more resources